Table 5 The influence of cyclophosphamide or ciclosporin on metabolism in IMN patients with coexisting DM

Accumulative GC dose (g)

6.2 ± 2.5

2.2 ± 0.9

< 0.001

 Pre-treatment FBG (mmol/L)

9.6 ± 3.4

8.4 ± 4.5

0.516

 Post-treatment FBG (mmol/L)

5.8 ± 1.5

5.9 ± 1.5

0.826

 Changes of FBG (mmol/L)

−2.8(−5.0, −1.0)

−1.2(−3.6, 0.2)

0.110

 Goal Attainment Rates of FBG (%)

62.5%

70%

0.701

 Pre-treatment uric acid (μmol/L)

376.5 ± 63.9

428.2 ± 123.4

0.272

 Post-treatment uric acid (μmol/L)

351.1 ± 67.5

418.7 ± 142.1

0.213

 Changes of uric acid (μmol/L)

−12.5(−101.3,56.5)

8.5(− 107.9,75.8)

0.672

 Goal Attainment Rates of uric acid (%)

87.5%

70%

0.334

 Pre-treatment CHOL (mmol/L)

7.2 ± 2.4

8.7 ± 3.0

0.196

 Post-treatment CHOL (mmol/L)

4.6 ± 0.8

4.6 ± 2.8

0.929

 Changes of CHOL (mmol/L)

−2.0(−5.6,0.1)

−3.5(−6.2, −1.2)

0.940

 Goal Attainment Rates of CHOL (%)

87.5%

55%

0.105

 Pre-treatment TG (mmol/L)

3.2 ± 2.7

3.3 ± 1.7

0.898

 Post-treatment TG (mmol/L)

1.8 ± 0.8

2.2 ± 1.0

0.391

 Changes of TG (mmol/L)

−0.9(−2.3, −0.3)

−0.6(− 2.5,0)

0.709

 Goal Attainment Rates of TG (%)

50%

40%

0.629

 Pre-treatment HDL (mmol/L)

1.5 ± 0.6

1.5 ± 0.4

0.982

 Post-treatment HDL (mmol/L)

1.4 ± 0.5

1.5 ± 0.6

0.617

 Changes of HDL (mmol/L)

−0.2(−0.3,0)

0(−0.3,0)

0.533

 Goal Attainment Rates of HDL (%)

50%

60%

0.629

 Pre-treatment LDL (mmol/L)

4.4 ± 1.6

5.4 ± 2.0

0.221

 Post-treatment LDL (mmol/L)

2.7 ± 0.7

2.3 ± 2.0

0.634

 Changes of LDL (mmol/L)

−1.7(−3.5,0.2)

−3.7(−4.6, −1.0)

0.784

 Goal Attainment Rates of LDL (%)

100%

60%

0.063